Skip to main content

Utility of LHRH antagonists for advanced prostate cancer.

Publication ,  Journal Article
Moul, JW
Published in: Can J Urol
April 2014

INTRODUCTION: Androgen deprivation therapy (ADT) is the lynchpin of treatment for advanced prostate cancer. Prescribing physicians and patients have a choice between orchiectomy, luteinizing hormone releasing hormone (LHRH) agonists, combined androgen deprivation (CAD) or LHRH antagonists. MATERIALS AND METHODS: Literature relating to the use of LHRH antagonists in the management of prostate cancer was reviewed. RESULTS: Abarelix was the first-in-class LHRH pure antagonist that was Food and Drug Administration (FDA) approved in 2003. Due to a variety of concerns including hypersensitivity reactions it was withdrawn from the United States (U.S.) market in 2005. The only currently commercially available LHRH antagonist in the U.S. is degarelix available as a once-a-month depot injection. The potential clinical advantage of degarelix compared to the LHRH agonists is the very rapid and sustained testosterone suppression with no identifiable physiological or clinical testosterone surge or flare. The main disadvantage of degarelix compared to the LHRH agonists is the monthly dosing and the inconvenience for some patients and practices. Recent studies tout improved disease control for degarelix compared to monthly leuprolide acetate; however, these results remain controversial. CONCLUSIONS: The rapid T-suppression achieved with degarelix may provide a clinical benefit for various groups of men with advanced or locally advanced disease.

Duke Scholars

Published In

Can J Urol

ISSN

1195-9479

Publication Date

April 2014

Volume

21

Issue

2 Supp 1

Start / End Page

22 / 27

Location

Canada

Related Subject Headings

  • Testosterone
  • Prostatic Neoplasms
  • Oligopeptides
  • Neoplasm Staging
  • Male
  • Humans
  • Gonadotropin-Releasing Hormone
  • Disease Progression
  • Cost-Benefit Analysis
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moul, J. W. (2014). Utility of LHRH antagonists for advanced prostate cancer. Can J Urol, 21(2 Supp 1), 22–27.
Moul, Judd W. “Utility of LHRH antagonists for advanced prostate cancer.Can J Urol 21, no. 2 Supp 1 (April 2014): 22–27.
Moul JW. Utility of LHRH antagonists for advanced prostate cancer. Can J Urol. 2014 Apr;21(2 Supp 1):22–7.
Moul, Judd W. “Utility of LHRH antagonists for advanced prostate cancer.Can J Urol, vol. 21, no. 2 Supp 1, Apr. 2014, pp. 22–27.
Moul JW. Utility of LHRH antagonists for advanced prostate cancer. Can J Urol. 2014 Apr;21(2 Supp 1):22–27.

Published In

Can J Urol

ISSN

1195-9479

Publication Date

April 2014

Volume

21

Issue

2 Supp 1

Start / End Page

22 / 27

Location

Canada

Related Subject Headings

  • Testosterone
  • Prostatic Neoplasms
  • Oligopeptides
  • Neoplasm Staging
  • Male
  • Humans
  • Gonadotropin-Releasing Hormone
  • Disease Progression
  • Cost-Benefit Analysis
  • Antineoplastic Agents